Considering recent evidence that TLL1 rs17047200 is a novel risk variant for fibrosis progression and liver cancer in patients with chronic hepatitis C [25,26], we examined its potential role in MAFLD. The gene discussed is TLL1; the disease is chronic hepatitis C virus infection.